Marsha Blackburn

07/21/2026 | Press release | Distributed by Public on 07/21/2026 11:51

Blackburn Introduces Legislation to Increase Domestic Production of Critical Medical Supplies

Blackburn Introduces Legislation to Increase Domestic Production of Critical Medical Supplies

July 21, 2026

WASHINGTON, D.C. - U.S. Senator Marsha Blackburn (R-Tenn.) introduced the Our Nation's Supply chain for Healthcare has Over Reliance Elsewhere Act (ONSHORE) Manufacturing Act to encourage the domestic production of critical medical products through targeted tax incentives designed to increase investment, strengthen supply chain resilience, and support American manufacturing:

"America's dependence on China and other foreign nations for critical medical supplies is a national security threat that puts the lives of Americans at risk," said Senator Blackburn. "The ONSHORE Manufacturing Act would cut red tape with smart tax incentives to bring production home, protect our supply chains, and ensure we never face shortages that endanger patients during a crisis."

BACKGROUND

  • The United States relies heavily on foreign countries, including China, for many of the medicines, medical devices, and active pharmaceutical ingredients (APIs) used by American patients every day.
  • This dependence creates vulnerabilities in the healthcare supply chain and leaves the United States exposed to disruptions caused by public health emergencies, natural disasters, geopolitical conflicts, and foreign export restrictions.
  • The COVID-19 pandemic highlighted these risks when shortages of medicines, personal protective equipment, and diagnostic materials disrupted patient care across the country. These challenges demonstrated the need for a stronger domestic manufacturing base for critical medical products.
  • Reliance on foreign supply chains is not only a healthcare issue but also a national security concern. Strengthening domestic manufacturing capacity can help ensure the United States has reliable access to the medicines and medical products needed during emergencies while reducing dependence on foreign competitors.

ONSHORE MANUFACTURING ACT

  • The ONSHORE Manufacturing Act would expand domestic manufacturing capacity and improve supply chain resilience products through key provisions, including a:

o 10.5% Domestic Manufacturing Production Credit that would help support long-term, U.S.-based production and employment;

o 30% Advanced Manufacturing Equipment Credit that would encourage investments in advanced manufacturing equipment used to produce critical medicines, APIs, biologics, medical devices, and medical countermeasures in the U.S.; and

o 30% Facility Modernization Credit that would support investment needed to upgrade and modernize manufacturing facilities to meet federal requirements while expanding domestic production capacity.

  • The bill would also require annual reports from the Internal Revenue Service, U.S. Department of Veterans Affairs, U.S. Department of War, and Food and Drug Administration evaluating the impact of the legislation on domestic manufacturing capacity, Buy American procurement compliance, supply chain resilience, and drug and device shortages.

Click here for bill text.

ENDORSEMENTS

This legislation is supported by DeRoyal Industries, Premier, Inc., Retractable Technologies, and the Securing America's Medicines and Supply, Inc. (SAMS Coalition):

"The COVID-19 pandemic exposed vulnerabilities in our healthcare supply chain, especially in the availability of critical items like personal protective equipment," said Brian DeBusk, President and CEO of DeRoyal. "Safeguarding the healthcare sector's ability to manage risk and respond effectively to emergencies is essential to our national security. Strengthening domestic manufacturing is a vital step toward building a more resilient and reliable supply chain."

"Premier Inc. supports the introduction of the ONSHORE Manufacturing Act to strengthen the resilience of the nation's healthcare supply chain. Ongoing global disruptions underscores the risks of overreliance on foreign manufacturing for critical medical products. Targeted, predictable tax incentives-like those included in this legislation-can help drive sustainable investment in domestic production, expand capacity and improve the availability of essential medicines and supplies for providers and patients," said John Knapp, Vice President, Advocacy, Premier, Inc.

"The ONSHORE Manufacturing Act is the spark American manufacturers need to rebuild our domestic medical base. This legislation ensures that healthcare providers have uninterrupted access to safe, American-made medical products. We are proud to support Senator Blackburn's efforts in safeguarding our public health infrastructure," said Retractable Technologies, Inc.

"By establishing targeted tax credits for domestic manufacturers, the ONSHORE Manufacturing Act represents a historic opportunity for domestic innovation, the creation of high-skilled American jobs, and the long-term resilience of our healthcare infrastructure," said Craig Burton, Chair, SAMS Coalition.

Marsha Blackburn published this content on July 21, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 21, 2026 at 17:51 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]